Sana Biotechnology announced six-month follow-up results from a first-in-human study transplanting HIP-modified (hypoimmune) allogeneic islet cells (UP421) into a...

Revolution Medicines received Breakthrough Therapy Designation from the FDA for daraxonrasib, its RAS(ON) inhibitor, targeting previously treated metastatic pancreatic...

Cue Biopharma received positive Pre-Investigational New Drug (Pre-IND) feedback from the FDA for CUE-401, a first-in-class bispecific molecule designed...

BioVie Inc. announced that a poster detailing the decentralized design and patient experience of its Phase 2 SUNRISE-PD clinical...

Inventprise, a clinical-stage vaccine company, published preclinical study results in Vaccine Journal demonstrating the potential of their bivalent SARS-CoV-2...

Actuate Therapeutics announced positive results from a Phase 2 trial of elraglusib combined with gemcitabine/nab-paclitaxel (GnP) as a first-line...

Veru Inc. announced positive topline results from the maintenance extension of its Phase 2b QUALITY clinical trial for enobosarm....

Quoin Pharmaceuticals announced that the FDA granted Rare Pediatric Disease Designation to QRX003 for treating Netherton Syndrome, a rare...

PharmaTher Holdings Ltd. has been granted a U.S. patent for using ketamine to treat Amyotrophic Lateral Sclerosis (ALS), bolstering...

Regeneron and Sanofi announced FDA approval of Dupixent (dupilumab) for bullous pemphigoid (BP) in adults. This approval is based...